Operator and manager of outpatient physical therapy clinics across the United States through partnerships with local therapists.
Operator and manager of outpatient physical therapy clinics across the United States through partnerships with local therapists.
Is paid per patient visit by health insurers, Medicare and workers' compensation insurers, so reimbursement rates and visit counts decide revenue. It usually owns a majority of each clinic while the therapist who runs it holds a minority share, tying local managers' pay to results. Growth comes from buying practices and opening clinics.
Moat: narrow (scale, distribution). Local physician/therapist partnership model builds trust and referral relationships in a fragmented market.
Headquarters: Houston, Texas · Founded: 1990 · Employees: 7,294
Size U.S. Physical Therapy (USPH) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.42B, the 2000th largest of 3,085 United States companies the cockpit tracks. Shares closed at $95.43 on 18 Nov 2026.
Performance Over six months the shares gained 53.3%, against +14.0% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 10.4% over the last twelve months (peer median +5.9%); the operating margin is 10.2% (peer median 4.7%).
Valuation It trades at 29.4× forward earnings against a peer median of 23.7× (8th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.1 points below its cost of capital (9.7% WACC).
Short interest Short interest is 7.6% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $838M | $781M | $671M | $605M | $553M |
| Revenue growth | — | +16% | +11% | +9% | — |
| Gross profit | $147M | $156M | $130M | $112M | $103M |
| EBITDA | $108M | $104M | $84.3M | $85.3M | $80.7M |
| Net income | -$20.2M | $21.6M | $27.7M | $18.1M | $29.3M |
| Free cash flow | $70.5M | $62.4M | $66.8M | $73.5M | $51.5M |
| Capital expenditure | $19.7M | $14.1M | $9.19M | $9.29M | $8.25M |
| Total debt | $420M | $315M | $295M | $259M | $295M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| U.S. Physical Therapy USPH | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% |
| Concentra Group Holdings Parent CON | $5.31B | +65% | +12% | 17% | 22.3× | 3.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | USPH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.7% | -1.6% | 4th highest of 21 |
| 6-month return | +53.3% | +14.0% | 3rd highest of 21 |
| Distance from 52-week high | -6.3% | -23.8% | 4th highest of 21 |
| Revenue growth (TTM) | +10.4% | +5.9% | 9th highest of 21 |
| Operating margin | 10.2% | 4.7% | 6th highest of 21 |
| Forward P/E | 29.4× | 23.7× | 8th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 18.8% | 6.5% | 5th most demanding of 15 |
| Growth delivered (Del g) | +13.0% | +8.1% | 6th highest of 15 |
| Hurdle (Req g minus delivered) | +5.7 pp | +1.3 pp | 7th most demanding of 15 |
| ROIC minus cost of capital | -4.1 pp | -3.1 pp | 9th lowest of 20 |
| EV / EBITDA | 20.0× | 10.7× | 6th most expensive of 14 |
| Net debt / EBITDA | 3.5× | 1.7× | 7th most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 16.0× | n/a | n/a |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 8.2× | 6.8% | +6.5% |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 19.5× | 7.3% | +18.9% |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 23.7× | 20.7% | +19.4% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | n/a | n/a | n/a |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 44.5× | 32.4% | +10.5% |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 63.0× | 40.4% | +16.7% |
| Dian Diagnostics 300244.SZ | China | $1.70B | +1% | -5% | 9% | 21.8× | 0.3% | -1.1% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 6.5× | -18.0% | +253.5% |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 10.6× | 6.3% | +7.7% |
| Emeis EMEIS.PA | France | $1.78B | -33% | +4% | 3% | n/a | 21.2% | +8.5% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.86B | +5% | -3% | 7% | 29.9× | 5.4% | -6.1% |